The risk of second primary malignancy is increased in differentiated thyroid cancer patients with a cumulative (131)I dose over 37 GBq.

@article{Khang2015TheRO,
  title={The risk of second primary malignancy is increased in differentiated thyroid cancer patients with a cumulative (131)I dose over 37 GBq.},
  author={Ah Reum Khang and Sun Wook Cho and Hoon Sung Choi and Hwa young Ahn and Won Sang Yoo and Kyung Won Kim and Keon Wook Kang and Ka Hee Yi and Do Joon Park and Dong Soon Lee and June Key Chung and Bo Youn Cho and Young Joo Park},
  journal={Clinical endocrinology},
  year={2015},
  volume={83 1},
  pages={117-23}
}
BACKGROUND The aim of this study was to investigate the risk factors for second primary malignancy (SPM) diagnosed after differentiated thyroid cancer (DTC). METHODS A total of 2468 DTC patients who underwent thyroidectomy were reviewed. SPM was defined as a non-thyroidal malignancy, diagnosed at least 1 year after the diagnosis of thyroid cancer. Patients were divided into five groups according to cumulative (131)I dose: very high-activity (≥ 37.0 GBq), high-activity (22.3-36.9 GBq… CONTINUE READING